BTIG analyst Ryan Zimmerman reiterated a Buy rating on Staar Surgical (STAA – Research Report) today and set a price target of $98.00. The company’s shares closed last Wednesday at $63.86, close to its 52-week low of $54.29.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 13.2% and a 45.8% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Zimmer Biomet Holdings, and Organogenesis Holdings.
Currently, the analyst consensus on Staar Surgical is a Strong Buy with an average price target of $92.75, representing a 53.9% upside. In a report issued on April 26, Canaccord Genuity also maintained a Buy rating on the stock with a $89.00 price target.
The company has a one-year high of $163.08 and a one-year low of $54.29. Currently, Staar Surgical has an average volume of 504.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.
Read More on STAA:
- Shaw and Partners Reaffirms Their Buy Rating on Audinate Group Ltd. (AUDGF)
- BMO Capital Sticks to Its Buy Rating for Host Hotels & Resorts (HST)
- Kura Oncology (KURA) Receives a Buy from Brookline Capital Markets
- Deutsche Bank Reaffirms Their Buy Rating on Ryman (RHP)
- BMO Capital Thinks Sabra Healthcare REIT’s Stock is Going to Recover